CoreLab Partners, an independent core lab providing centralized cardiac safety services and medical imaging assessment, has launched new imaging capabilities targeted at the utilization of independent central image review in the detection of early Alzheimer’s disease.

“Recognizing the ongoing evolution of magnetic resonance imaging (MRI), positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging in dementia-related clinical trials, CoreLab Partners has put into place a team of knowledgeable experts combined with advanced technological tools to ensure current and emerging image assessment needs are met,” said Dr. Michael Woehler, president and CEO, CoreLab.

He added, “This exciting new capability is a natural extension of our industry-leading suite of imaging science solutions and marks a significant milestone in the utilization of scientifically validated tools designed to accurately quantify brain structure volumetric data.”